K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 45.8 HKD -1.51% Market Closed
Market Cap: 12.8B HKD

Intrinsic Value

KeyMed Biosciences Inc's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one KeyMed Biosciences Inc stock under the Base Case scenario is 78.8 HKD. Compared to the current market price of 45.8 HKD, KeyMed Biosciences Inc is Undervalued by 42%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
78.8 HKD
Undervaluation 42%
Intrinsic Value
Price
K
Base Case Scenario
Compare KeyMed Biosciences Inc to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about KeyMed Biosciences Inc?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about KeyMed Biosciences Inc
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
KeyMed Biosciences Inc

Balance Sheet Decomposition
KeyMed Biosciences Inc

Current Assets 2.5B
Cash & Short-Term Investments 2.2B
Receivables 69.5m
Other Current Assets 240.9m
Non-Current Assets 1.3B
Long-Term Investments 210m
PP&E 1.1B
Intangibles 9.7m
Other Non-Current Assets 5.4m
Efficiency

Free Cash Flow Analysis
KeyMed Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
KeyMed Biosciences Inc

Revenue
428.1m CNY
Cost of Revenue
-12.2m CNY
Gross Profit
415.9m CNY
Operating Expenses
-1B CNY
Operating Income
-591.5m CNY
Other Expenses
76.2m CNY
Net Income
-515.2m CNY
Fundamental Scores

Profitability Score
Profitability Due Diligence

KeyMed Biosciences Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Exceptional Gross Margin
Strong 3Y Average Gross Margin
Operating Margin is Increasing
25/100
Profitability
Score

KeyMed Biosciences Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

KeyMed Biosciences Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
56/100
Solvency
Score

KeyMed Biosciences Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
KeyMed Biosciences Inc

Wall Street analysts forecast KeyMed Biosciences Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KeyMed Biosciences Inc is 61.17 HKD with a low forecast of 55.55 HKD and a high forecast of 74.29 HKD.

Lowest
Price Target
55.55 HKD
21% Upside
Average
Price Target
61.17 HKD
34% Upside
Highest
Price Target
74.29 HKD
62% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

KeyMed Biosciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for KeyMed Biosciences Inc is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one KeyMed Biosciences Inc stock?

The intrinsic value of one KeyMed Biosciences Inc stock under the Base Case scenario is 78.8 HKD.

Is KeyMed Biosciences Inc stock undervalued or overvalued?

Compared to the current market price of 45.8 HKD, KeyMed Biosciences Inc is Undervalued by 42%.

Back to Top